|Articles|January 28, 2015

Merck and Novo Nordisk Join TransCelerate

Author(s)Applied Clinical Trials Editorial Staff

TransCelerate BioPharma Inc. today announced two new members, Merck & Co. Inc., and Novo Nordisk, to the biopharmaceutical non-profit organization.

TransCelerate BioPharma announced two new members, Merck & Co. Inc., and Novo Nordisk, to the biopharmaceutical non-profit organization, bringing the total number of members to 23. In addition, TransCelerate has appointed Briggs Morrison, MD, Executive Vice President, Global Medicines Development at AstraZeneca, to the position of Chair of the Board of Directors. Read the full release here.

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Merck and Novo Nordisk Join TransCelerate

Related Content

Beyond Patient Centricity: What Rare Disease Research Gets Right

The Unquantified Value of RBQM: Reduced Rework, Data Integrity, and Inspection Readiness

ACT Brief: Time Savings as RBQM Value Driver, FDA Tightens Foreign Trial Oversight, and Trusted Research Environments Versus Flat Files

FDA Reaffirms GCP Standards Amid Growing Concerns Over Foreign Clinical Trial Data

Why Time Savings Is the Largest Driver of RBQM's Financial Value

Trending on Applied Clinical Trials Online

Beyond Patient Centricity: What Rare Disease Research Gets Right

AI Moves Patient Recruitment from Trial Bottleneck to Competitive Edge: A 2026 Perspective

Fortrea to Acquire Worldwide Clinical Trials' Early Phase Services Division in $45 Million Deal

FDA Reaffirms GCP Standards Amid Growing Concerns Over Foreign Clinical Trial Data

ACT Brief: Time Savings as RBQM Value Driver, FDA Tightens Foreign Trial Oversight, and Trusted Research Environments Versus Flat Files